2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 353-355
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

451 O-glycosylated CD43 is a pan-immune checkpoint for TP53-mutated acute myeloid leukemia

Yun Li, MS, Jordan Yong Ming Tan, RPh2, Chuqi Wang, PhD3, Javier Sanmartin Martinez, MSc, BSc4, Bob van Gasteren5, Shaista Shabbir Jasdanwala, MSc6, Yuhan Wang, MSc7, Karanpreet Bhatia, PhD8, Ankit Jana, MTech9, Xiao Xian Lin, BSc10, Bofei Wang, PhD11, Yash Manish Agrawal12, Hussein Ali Abbas, MD, PhD13, Anna Marneth, PhD14, Shruti Bhatt, PhD15
1 Emory University, Atlanta, Georgia, United States, National University of Singapore, Singapore, Singapore
2 National University of Singapore, Singapore, Singapore
3 National University of Singapore, Singapore, Singapore
4 Radboud University Medical Center, Radboud Institute for Medical Innovation, Nijmegen, Netherlands
5 Radboud University Medical Center, Radboud Institute for Medical Innovation, Nijmegen, Netherlands
6 National University of Singapore, Singapore, Singapore
7 Emory University, Atlanta, Georgia, United States, National University of Singapore, Singapore, Singapore
8 Emory University, Atlanta, Georgia, United States
9 National University of Singapore, Singapore, Singapore
10 National University of Singapore, Singapore, Singapore
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 National University of Singapore, Singapore, Singapore
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 Radboud University Medical Center, Radboud Institute for Medical Innovation, Nijmegen, Netherlands
15 Emory University, Atlanta, Georgia, United States

TP53-inactivation (mutation or deletion) in acute myeloid leukemia (AML) results in profound treatment resistance to conventional cytotoxic chemotherapies, targeted therapies, and even allogeneic stem cell transplantation. Loss of wild-type (WT) p53 function gives rise to apoptosis blockade that represents a major barrier to improving outcomes with cytotoxic chemotherapy or targeted therapy alone. This emphasizes the urgent need for identifying novel immunotherapeutic targets capable of overcoming immune resistance in TP53-inactivated AML.

To search for novel immunotherapeutic targets in TP53-inactivated AML, we performed unbiased genome-wide CRISPR knockout screens in isogenic MOLM-13 AML cells carrying TP53 wild-type, R248Q mutant, or TP53 knockout, challenged with TCR-T or NK-92 cells. Across genotypes and effector cell types, resistance hits converged on a shared O-glycosylation pathway, with CD43 (SPN) emerging as the top resistance gene alongside a conserved O-glycosylation/sialylation module (C1GALT1, SLC35A2, SLC39A9, GNPNAT1, and NANS), nominating CD43 as a novel, TP53-independent, pan-immune checkpoint. A parallel CRISPR screen in THP-1 macrophages (TP53 WT) independently identified CD43, C1GALT1, and C1GALT1C1 as top resistance hits, supporting relevance of this pathway across both innate and adaptive immune effectors.

CD43 is a heavily O-glycosylated and sialylated mucin-like glycoprotein expressed on hematopoietic cells. Functional validation using CD43 knockout and the CD43-blocking antibody MEM59 significantly enhanced CD123 CAR-T, TCR-T and NK cell-mediated cytotoxicity, as well as macrophage-mediated phagocytosis, against TP53-inactivated AML cells and primary tumors. C1GALT1 or C1GALT1C1 knockouts similarly enhanced immune killing of AML cells. CD43 knockout also reduced the CAR-T cell exhaustion phenotype (sustained CD25+ activation) seen against TP53-inactivated AML. Pharmacologic disruption of the O-glycosylation/sialylation pathway with benzyl-α-GalNAc, AC5GalNTGc, the SLC35A2 inhibitor itraconazole, and the sialylation inhibitor sialostatin phenocopied genetic CD43 disruption, enhancing immune-mediated killing regardless of TP53 status.

Mechanistically, quantitative proteomics and proximity-labelling mass spectrometry showed that CD43 loss increases surface exposure of pro-immune ligands, including ICAM-1 and HLA-A/B/C, which are central to LFA-1-dependent immune synapse formation. CD43 resides in close proximity to these ligands at the plasma membrane and sterically shields them from recognition by T and NK cells, limiting immune engagement. Additionally, G-baToN-based cell-cell contact assays confirmed that CD43 impedes cell-cell contact between AML and immune cells. In macrophage co-culture assays, this shielding effect was independent of SIGLEC1/7 signalling and changes in cell-surface zeta potential, indicating that canonical lectin engagement and electrostatic repulsion are not primary drivers.

Clinically, CD43 is significantly overexpressed on malignant AML blasts relative to normal blood. In both BeatAML and TCGA cohorts, CD43-high AML correlates with an immunosuppressive tumor microenvironment, marked by increased M2 macrophage abundance and a higher M2/M0 macrophage ratio. Bulk and single-cell transcriptomic analyses of TP53-mutant AML confirmed significantly higher CD43 expression in the myeloid/blast compartment relative to non-myeloid, erythroid, and lymphoid compartments. Importantly, this CD43 upregulation was preserved despite TP53 mutation or deletion, positioning CD43 as a therapeutically attractive target in the highly aggressive TP53 mutated subgroup of patients. In vivo, NSG mice engrafted with CD43 knockout R248Q isogenic AML cells showed significantly extended survival compared to mice engrafted with CD43-competent R248Q cells, providing functional in vivo validation that CD43 loss restrains TP53-mutant AML growth.

Together, these data establish CD43 as a pan-immune checkpoint that restrains phagocytosis, T cell, and NK cell-mediated killing of AML through a shared glycosylation/sialylation program. Importantly, our study reveals for the first time that CD43 functions independently of TP53 status. Critically, our findings offer a rare and novel immunotherapeutic strategy for treatment-refractory, high-risk TP53-mutated patient populations.

Yun Li, MS: No relevant conflicts of interest to declare.